1. Cabazitaxel is recommended for the treatment of hormone-resistant prostate cancer, also referred to as castration-resistant prostate cancer, which has metastasis (spread to other parts of the body) and has progressed despite prior docetaxel treatment.
2. Administration: Cabazitaxel is administered intravenously (IV), commonly as an injection given once every three weeks into a vein.
3. Cabazitaxel is typically administered in doses of 25 mg/m2 once every three weeks. The Cabazitaxel Injection you stated has a concentration of 60mg/1.5ml, which refers to the medication's concentration in the vial. The dose provided will be depending on the patient's body surface area.
4. Pre-medication: To help lower the chance of specific adverse effects, patients frequently get pre-medication with corticosteroids, such as prednisone.
5. Side Effects: Common Cabazitaxel side effects may include peripheral neuropathy (numbness or tingling in the hands and feet), exhaustion, nausea, diarrhoea, and bone marrow suppression (leading in low blood cell counts).
6. Monitoring: To manage side effects and guarantee treatment safety, patients receiving Cabazitaxel need regular monitoring of blood cell counts and other pertinent data.
A licenced healthcare practitioner should decide whether to administer Cabazitaxel Injection to a patient, taking into account their unique medical history and current state, as they would with any cancer treatment. If you or someone you know has been given Cabazitaxel Injection 60mg/1.5ml or has questions about the drug, it's vital to speak with a medical professional for complete details, possible side effects, and instructions on how to take it.